Comparative Pharmacology
Head-to-head clinical analysis: PYLORI CHEK BREATH TEST versus THYROGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYLORI CHEK BREATH TEST versus THYROGEN.
PYLORI-CHEK BREATH TEST vs THYROGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Urea labeled with 13C is hydrolyzed by urease enzyme produced by Helicobacter pylori, producing 13CO2 which is exhaled and detected in breath.
Recombinant human thyroid-stimulating hormone (TSH) that binds to TSH receptors on thyroid follicular cells, stimulating iodine uptake, thyroglobulin synthesis, and release of thyroid hormones.
Adults: 75 mg of 13C-urea dissolved in 75 mL of water, administered orally as a single dose. Breath samples collected at baseline and 30 minutes post-dose.
0.9 mg intramuscular injection every 24 hours for 2 doses, or 1.2 mg orally as a single dose.
None Documented
None Documented
The elimination half-life of 13C-urea is approximately 0.5–1 hour in patients with normal renal function, reflecting rapid renal clearance. In severe renal impairment, half-life may be prolonged up to 7–10 hours.
12-15 hours (terminal elimination half-life in patients with normal renal function; may be prolonged in renal impairment). Clinically, TSH levels peak by 3 hours after IM injection and return to baseline by 24-48 hours.
13C-urea is excreted renally as intact urea (approximately 85%) and as 13CO2 in breath (approximately 15%). Fecal elimination is negligible. In renal impairment, breath 13CO2 excretion may increase as renal clearance decreases.
Primarily renal (thyrotropin is a glycoprotein hormone; intact hormone is minimally excreted unchanged; metabolic degradation products are eliminated renally). After IV administration, approximately 96% of the dose is recovered in urine within 24 hours as low molecular weight degradation products. Biliary/fecal excretion is negligible (<1%).
Category C
Category C
Diagnostic Agent
Diagnostic Agent